Cargando…

A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas

Diffuse large B-cell lymphoma—not otherwise specified (DLBCL-NOS) is a large and heterogeneous subgroup of non-Hodgkin lymphoma. DLBCL can be subdivided into germinal centre B-cell like (GCB) and activated B-cell like (ABC or non-GCB) using a gene-expression based or an immunohistochemical approach....

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Meeren, L. E., Kluiver, J., Rutgers, B., Alsagoor, Y., Kluin, P. M., van den Berg, A., Visser, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788715/ https://www.ncbi.nlm.nih.gov/pubmed/31603917 http://dx.doi.org/10.1371/journal.pone.0223260

Ejemplares similares

Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
por: Batlle-López, Ana, et al.
Publicado: (2016)

Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma
por: Boltežar, Lučka, et al.
Publicado: (2018)

Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma
por: Xu, Xin, et al.
Publicado: (2021)

Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis
por: Tsygankova, Svetlana, et al.
Publicado: (2022)

Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma
por: Thomsen, Emil Aagaard, et al.
Publicado: (2020)

CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain
por: Cho, Junhun, et al.
Publicado: (2022)

Primary Cutaneous DLBCL Non-GCB Type: Challenges of a Rare Case
por: Sica, Antonello, et al.
Publicado: (2020)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
por: Zhu, H., et al.
Publicado: (2022)

Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma
por: Ma, Jiao, et al.
Publicado: (2015)

Primary Type3 (Non-ABC, Non-GCB) Subtype of Extranodal Diffuse Large B-Cell Lymphoma of the Thyroid Bearing No MYD88 Mutation by Padlock Probe Hybridization
por: Nishi, Yukiko, et al.
Publicado: (2017)

Enrichment of TP53 alterations within GCB-like DNA subclassifications of diffuse large B-cell lymphoma after transition from de-novo to relapsed or refractory disease
por: Lund, Shelby, et al.
Publicado: (2022)

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
por: Geng, Hongzhi, et al.
Publicado: (2023)

Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas
por: Wu, Rui, et al.
Publicado: (2016)

Sir Alfred Keogh, G.C.B., M.D.: The Director-General of the Army Medical Service
Publicado: (1917)

Sir Alfred Keogh, G.C.B. M.D.: Rector of the Imperial College of Science and Technology
Publicado: (1918)

Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients
por: Wang, Jing, et al.
Publicado: (2016)

SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients
por: Rüetschi, Ulla, et al.
Publicado: (2015)

Super-SILAC Allows Classification of Diffuse Large B-cell Lymphoma Subtypes by Their Protein Expression Profiles
por: Deeb, Sally J., et al.
Publicado: (2012)

Targeting PIN-1 Attenuates GCB DLBCL Cell Proliferation Through Inhibition of PI3K/AKT Signaling
por: Yang, Haijun, et al.
Publicado: (2020)

Germinal Center B Cell-Like (GCB) and Activated B Cell-Like (ABC) Type of Diffuse Large B Cell Lymphoma (DLBCL): Analysis of Molecular Predictors, Signatures, Cell Cycle State and Patient Survival
por: Blenk, S., et al.
Publicado: (2007)

GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner
por: Xia, Zhizhou, et al.
Publicado: (2021)

P1196: ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL
por: Qu, Chang-Ju, et al.
Publicado: (2023)

Report to the Right Honourable Lord Panmure, G.C.B., &c., of the Proceedings of the Sanitary Commission Dispatched to the Seat of War in the East, 1855–6
Publicado: (1858)

P1285: IN VIVO IMPACT OF ABERRANT OVEREXPRESSION OF C-REL NF-ΚB SUBUNIT IN GERMINAL CENTER B-LYMPHOCYTES: A TUMOR ONCOGENIC EVENT IN GCB-DLBCLS
por: Prévaud, L., et al.
Publicado: (2022)

The Role of the MYC/miR-150/MYB/ZDHHC11 Network in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
por: Ziel-Swier, Lotteke J. Y. M., et al.
Publicado: (2022)

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability
por: Pastores, Gregory M., et al.
Publicado: (2014)

R-CHOP方案和R-DA-EPOCH方案一线治疗non-GCB型弥漫大B细胞淋巴瘤回顾性研究
Publicado: (2022)

P1185: ANTITUMOR ACTIVITY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R-CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DLBCL WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II STUDY.
por: Li, C., et al.
Publicado: (2022)

SuperSILAC Quantitative Proteome Profiling of Murine Middle Ear Epithelial Cell Remodeling with NTHi
por: Val, Stéphanie, et al.
Publicado: (2016)

Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma
por: Visser, Lydia, et al.
Publicado: (2016)

Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma
por: Nijland, Marcel, et al.
Publicado: (2018)

The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein–Barr virus presence and location within the tumor
por: Wu, R, et al.
Publicado: (2016)

CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma
por: Sattarzadeh, Ahmad, et al.
Publicado: (2015)

Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma
por: Slezak-Prochazka, Izabella, et al.
Publicado: (2015)

P1190: EFFICACY AND SAFETY OF SELINEXOR COMBINING WITH R-CHOP IN THE TREATMENT OF NEWLY DIAGNOSED HIGH RISK (IPI 3-5) GCB SUBTYPE DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE REAL-WORLD STUDY FROM CHINA.
por: Zhi-Ming, LI, et al.
Publicado: (2023)

Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma
por: Kleo, Karsten, et al.
Publicado: (2019)

Secretome Analysis of Skeletal Myogenesis Using SILAC and Shotgun Proteomics
por: Chan, C. Y. X'avia, et al.
Publicado: (2011)

Hepatic SILAC proteomic data from PANDER transgenic model
por: Athanason, Mark G., et al.
Publicado: (2016)

Relapse in stage I(E) diffuse large B‐cell lymphoma
por: Nijland, Marcel, et al.
Publicado: (2017)

Erratum: Lydia Visser et al. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma, Int. J. Mol. Sci. 2016, 17, 2127
por: Sattarzadeh, Ahmad, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a69ieh9fla7tmvt85evu0ea494